One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees. Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents. Researchers found 18F-rhPSMA-7.3 to have a high affinity and potential for low bladder activity. Dr. Wallis interviews Dr. Luckenbaugh on the important research coming out of the AUA meeting pertaining to kidney cancer. Dr. Ambinder interviews Dr. Scarpato on when focal therapy should be recommended as salvage therapy for BCR prostate cancer. The relevant updates to the guideline for upper tract urothelial carcinoma are provided by Dr. Peter Clark. A PC debate between Dr. Catalona and Dr. Cooperberg considered renaming Gleason 6 to remove the cancer terminology. Dr. Rini provided an overview of nccRCC, including data pertaining to response to IO monotherapy and IO/TKI combinations. There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research. The results of a new systematic review showed the evidence base regarding ICIs as adjuvant therapy in RCC is “mixed.” Dr. Neal Shore presented the results of the phase 3 randomized EMBARK study as a late-breaking abstract. Dr. Salami discusses the latest guideline update for early detection of prostate cancer at the AUA 2023 meeting. New research highlights real-world outcomes of targeted therapy and immunotherapy for patients with metastatic pRCC. Comparing outcomes of patients receiving consolidative nephrectomy after systemic immunotherapy vs cytoreductive surgery. During an afternoon plenary session, Dr. Jonathan Coleman presented the updates to the AUA guideline for UTUC. Active surveillance is not inferior to intervention for small renal masses suspicious for RCC, according to new research. Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC. IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC. Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial. A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.